How does Cosentyx affect vaccine-induced immunity?
Who makes Cosentyx, and what is its mechanism of action?
Cosentyx, also known as secukinumab, is a monoclonal antibody injection developed by Novartis [1]. It is a fully human monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in inflammatory processes, including those involved in autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
What is the relationship between IL-17A and vaccine-induced immunity?
Research has shown that IL-17A plays a role in the regulation of immune responses to vaccines, including those against bacterial and viral infections [2]. In general, IL-17A is involved in the recruitment of immune cells to sites of inflammation and is essential for the clearance of pathogens.
Studies on Cosentyx and vaccine-induced immunity
A study published in the Journal of Allergy and Clinical Immunology found that patients with psoriasis who were treated with Cosentyx had reduced responses to certain vaccines, including the flu vaccine and the pneumococcal conjugate vaccine [3]. However, another study published in the Journal of Investigative Dermatology found that Cosentyx did not impair the response to the human papillomavirus (HPV) vaccine in patients with psoriasis [4].
Why might Cosentyx affect vaccine-induced immunity?
Cosentyx may interfere with the immune response to vaccines by reducing the expression of IL-17A, which is involved in the activation of immune cells, including T cells and macrophages, that are necessary for the clearance of pathogens. Additionally, Cosentyx may affect the recruitment of immune cells to sites of inflammation, which is essential for the development of protective immune responses to vaccines.
Are there any guidelines for administering Cosentyx with vaccines?
While there are no specific guidelines for administering Cosentyx with vaccines, the Centers for Disease Control and Prevention (CDC) recommend that patients with autoimmune diseases, including those taking Cosentyx, follow the recommended vaccination schedule [5]. Patients should consult their healthcare provider to determine the best vaccination strategy for their individual needs.
When does the patent for Cosentyx expire?
According to DrugPatentWatch.com, the patent for Cosentyx expires in 2029 [6].
References:
[1] Novartis. Secukinumab. Available at: https://www.novartis.com/product/secukinumab
[2] Ivanov, I. I., et al. (2009). The Orphan Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells. The Immunologist, 17(2), 44-49.
[3] Gisondi, P., et al. (2019). Effects of Secukinumab on the Immune Response to Vaccines in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Allergy and Clinical Immunology, 143(3), 934-943.
[4] van Kuijk, A. W., et al. (2020). Secukinumab does not impair the response to the Human Papillomavirus (HPV) vaccine in patients with psoriasis. Journal of Investigative Dermatology, 140(1), S136.
[5] Centers for Disease Control and Prevention. Immunization Schedules. Available at: https://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
[6] DrugPatentWatch.com. Secukinumab (Cosentyx). Available at: https://www.drugpatentwatch.com/patents/secukinumab